You are reviewing a 68-year-old man with type 2 diabetes (HbA1c 64 mmol/mol), stage 3a CKD (eGFR 52 ml/min/1.73m²), and heart failure with reduced ejection fraction (LVEF 36%). His current diabetes medications are metformin 1g twice daily and gliclazide 160mg twice daily. He has had two episodes of hypoglycaemia in the past month (blood glucose 3.1 and 2.8 mmol/L). According to current evidence and guidelines, which medication adjustment would provide the most cardiovascular and renal benefit while reducing hypoglycaemia risk?
Q22
A 73-year-old woman with Parkinson's disease, type 2 diabetes, recurrent falls, and urinary incontinence is taking co-careldopa, pramipexole, tolterodine, metformin, atorvastatin, and amlodipine. Over the past 3 months, she has had four falls with no clear precipitant. Her lying blood pressure is 142/84 mmHg and standing blood pressure is 138/80 mmHg. Her Parkinson's symptoms are reasonably well controlled. What aspect of her medication regimen is most likely contributing to her falls?
Q23
During a practice audit, you identify a 67-year-old man with multimorbidity (ischaemic heart disease, heart failure with reduced ejection fraction, type 2 diabetes, COPD, and depression) who is taking 13 regular medications. His GP records show that his last comprehensive medication review was 26 months ago. He has had three unplanned hospital admissions in the past year. Which framework would be most appropriate for conducting a structured medication review for this patient?
Q24
A 75-year-old woman with heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, and osteoarthritis takes 11 regular medications. She has been admitted to hospital twice in the past 6 months with acute decompensated heart failure. During a comprehensive medication review, you discover she has been taking ibuprofen 400mg three times daily (purchased over-the-counter) for knee pain for the past 8 months. What is the primary mechanism by which NSAIDs have contributed to her heart failure decompensation?
Q25
A 72-year-old man with chronic kidney disease stage 4 (eGFR 25 ml/min/1.73m²), type 2 diabetes, gout, and hypertension attends for review. His medications include insulin, allopurinol 100mg daily, amlodipine, doxazosin, and sodium bicarbonate. He reports three episodes of acute gout in the past 4 months despite treatment. His serum urate is 485 µmol/L (target <360 µmol/L). What is the most appropriate adjustment to his urate-lowering therapy?
Q26
According to NICE Clinical Knowledge Summaries guidance on medication reviews in primary care, which statement best describes when a structured medication review should be prioritized?
Q27
A 69-year-old woman attends for a medication review. She has type 2 diabetes, hypertension, atrial fibrillation, and hypothyroidism. She reports feeling 'generally well' but mentions occasional episodes of light-headedness when standing. Her current medications include metformin, gliclazide, amlodipine, ramipril, bisoprolol, apixaban, and levothyroxine. Her blood pressure today is 118/68 mmHg (sitting) and 95/60 mmHg (standing). What is the most appropriate next step in managing her medications?
Q28
You are implementing a deprescribing initiative in your practice for patients with multimorbidity and polypharmacy. A 76-year-old man with heart failure (LVEF 42%), type 2 diabetes, hypertension, and previous stroke takes 14 regular medications including aspirin 75mg, clopidogrel 75mg, atorvastatin 80mg, ramipril 10mg, bisoprolol 10mg, furosemide 40mg, metformin 1g twice daily, sitagliptin 100mg, amlodipine 10mg, lansoprazole 30mg (started 4 years ago when dual antiplatelet therapy initiated), warfarin (INR target 2-3 for atrial fibrillation), levothyroxine 100mcg, and vitamin supplements. His stroke was 3.5 years ago. Which medication is most appropriate to consider for deprescribing?
Q29
A 66-year-old woman with rheumatoid arthritis, hypertension, type 2 diabetes, and recurrent urinary tract infections attends for medication review. Her medications include methotrexate 15mg weekly, folic acid 5mg weekly, sulfasalazine 1g twice daily, prednisolone 7.5mg once daily, omeprazole 20mg once daily, ramipril 5mg once daily, amlodipine 5mg once daily, metformin 1g twice daily, and she has been taking trimethoprim 200mg at night continuously for 9 months as prophylaxis prescribed by urology. Her most recent blood results show: eGFR 58 ml/min/1.73m², Hb 98 g/L (MCV 102 fL), WCC 3.2 × 10⁹/L. What is the most likely explanation for her blood results?
Q30
During a practice audit of medication reviews, you identify that 25% of patients over 75 years taking 10 or more medications have not had a structured medication review in the past 12 months. You are planning a quality improvement intervention. According to best practice guidance, which component is most essential to include in a structured medication review process for this population?
Chronic Disease Management UK Medical PG Practice Questions and MCQs
Question 21: You are reviewing a 68-year-old man with type 2 diabetes (HbA1c 64 mmol/mol), stage 3a CKD (eGFR 52 ml/min/1.73m²), and heart failure with reduced ejection fraction (LVEF 36%). His current diabetes medications are metformin 1g twice daily and gliclazide 160mg twice daily. He has had two episodes of hypoglycaemia in the past month (blood glucose 3.1 and 2.8 mmol/L). According to current evidence and guidelines, which medication adjustment would provide the most cardiovascular and renal benefit while reducing hypoglycaemia risk?
A. Stop gliclazide and add sitagliptin 50mg once daily
B. Reduce gliclazide to 80mg twice daily and add pioglitazone 15mg once daily
C. Stop gliclazide and add empagliflozin 10mg once daily (Correct Answer)
D. Continue current regimen but add acarbose 50mg three times daily with meals
E. Stop gliclazide and switch to insulin detemir starting at 10 units once daily
Explanation: ***Stop gliclazide and add empagliflozin 10mg once daily***- **SGLT2 inhibitors** like empagliflozin provide significant **cardiovascular and renal protection**, specifically reducing hospitalizations for **heart failure** and slowing **CKD progression**.- Stopping **gliclazide**, a sulfonylurea, directly addresses the patient's recent **hypoglycaemia** episodes while maintaininig glycemic control with a weight-neutral, low-hypoglycemia risk alternative.*Stop gliclazide and add sitagliptin 50mg once daily*- While **DPP-4 inhibitors** like sitagliptin have a low risk of **hypoglycaemia**, they are weight neutral and have not shown the same **cardioprotective or renoprotective** benefits as SGLT2 inhibitors.- In patients with established **heart failure**, SGLT2 inhibitors are the preferred add-on therapy according to current international guidelines (NICE, ADA, ESC).*Reduce gliclazide to 80mg twice daily and add pioglitazone 15mg once daily*- **Pioglitazone** is strictly contraindicated in patients with **heart failure** because it causes fluid retention and can exacerbate heart failure symptoms.- Maintaining any dose of **gliclazide** in a patient already experiencing symptomatic **hypoglycaemia** (BG < 3.0 mmol/L) remains a safety concern.*Continue current regimen but add acarbose 50mg three times daily with meals*- **Acarbose** has a very modest effect on **HbA1c** and lacks proven benefits for **heart failure with reduced ejection fraction (HFrEF)** or CKD.- Adding another agent while the patient is already experiencing frequent **hypoglycaemic episodes** on gliclazide does not address the primary safety issue.*Stop gliclazide and switch to insulin detemir starting at 10 units once daily*- Switching to **insulin** would likely increase the risk of further **hypoglycaemic events** and does not provide the specific disease-modifying benefits required for **HFrEF**.- Insulin therapy is usually reserved for when non-insulin therapies fail to achieve glycemic targets and won't address the patient's **heart failure** prognosis.
Question 22: A 73-year-old woman with Parkinson's disease, type 2 diabetes, recurrent falls, and urinary incontinence is taking co-careldopa, pramipexole, tolterodine, metformin, atorvastatin, and amlodipine. Over the past 3 months, she has had four falls with no clear precipitant. Her lying blood pressure is 142/84 mmHg and standing blood pressure is 138/80 mmHg. Her Parkinson's symptoms are reasonably well controlled. What aspect of her medication regimen is most likely contributing to her falls?
A. Orthostatic hypotension from co-careldopa and amlodipine
B. Anticholinergic burden from tolterodine affecting cognition and balance (Correct Answer)
C. Dopamine agonist-induced impulse control disorder affecting judgment
D. Statin-induced myopathy reducing muscle strength
E. Metformin-induced vitamin B12 deficiency affecting proprioception
Explanation: ***Anticholinergic burden from tolterodine affecting cognition and balance***
- **Tolterodine** is an antimuscarinic medication that adds to the **anticholinergic burden**, which is a significant risk factor for **falls, cognitive impairment, and delirium** in the elderly.
- In patients with **Parkinson's disease**, anticholinergics are particularly problematic as they can exacerbate existing balance issues and potentially worsen cognitive function, increasing fall risk.
*Orthostatic hypotension from co-careldopa and amlodipine*
- The measured blood pressure drop (4 mmHg systolic) is not significant enough to be classified as **orthostatic hypotension**, which requires a drop of at least 20 mmHg systolic or 10 mmHg diastolic.
- While both **co-careldopa** and **amlodipine** can cause hypotension, the absence of a significant drop in this case rules out orthostatic hypotension as the primary cause of falls.
*Dopamine agonist-induced impulse control disorder affecting judgment*
- **Pramipexole**, a dopamine agonist, is associated with **impulse control disorders** (e.g., pathological gambling, hypersexuality), which affect judgment but typically do not directly cause physical falls.
- The patient's **Parkinson's symptoms** are reported as well controlled, suggesting that the current dose of pramipexole is unlikely to be causing new or exacerbated motor symptoms leading to falls.
*Statin-induced myopathy reducing muscle strength*
- **Statin-induced myopathy** typically presents with symptoms such as **muscle pain, tenderness**, or **proximal muscle weakness**, often accompanied by elevated **creatine kinase** levels.
- The case description does not mention any signs or symptoms suggestive of myopathy, making it an unlikely cause for the recurrent falls in this patient.
*Metformin-induced vitamin B12 deficiency affecting proprioception*
- Long-term **metformin** use can lead to **vitamin B12 deficiency**, which may cause **peripheral neuropathy** and impair **proprioception**, contributing to falls.
- However, this process is usually gradual, and there are no specific findings in the patient's presentation, such as numbness or tingling, to suggest significant proprioceptive loss from B12 deficiency as the primary cause of acute falls.
Question 23: During a practice audit, you identify a 67-year-old man with multimorbidity (ischaemic heart disease, heart failure with reduced ejection fraction, type 2 diabetes, COPD, and depression) who is taking 13 regular medications. His GP records show that his last comprehensive medication review was 26 months ago. He has had three unplanned hospital admissions in the past year. Which framework would be most appropriate for conducting a structured medication review for this patient?
A. The Beers Criteria for potentially inappropriate medications in older adults
B. The STOPP/START criteria version 2 (Correct Answer)
C. The Medication Appropriateness Index (MAI)
D. The NO TEARS tool for medication review
E. The Anticholinergic Burden Scale
Explanation: ***The STOPP/START criteria version 2***- This is the most suitable framework for European/UK settings as it systematically addresses both **potentially inappropriate medications (STOPP)** and **potential prescribing omissions (START)** across physiological systems.- It is highly effective for managing **multimorbidity** and reducing **adverse drug reactions** in patients with polypharmacy and frequent hospital admissions.*The Beers Criteria for potentially inappropriate medications in older adults*- Primarily developed for the **US healthcare system**, it lacks recommendations for **medication omissions** (starting beneficial drugs).- While useful for identifying high-risk drugs, it is less comprehensive for a **structured medication review** in the UK context compared to STOPP/START.*The Medication Appropriateness Index (MAI)*- Provides a scoring system based on 10 criteria for each drug, but it is **time-consuming** and focuses on individual drug assessment rather than clinical outcomes.- It lacks specific **clinical triggers** for starting new, evidence-based therapies for chronic conditions like heart failure or diabetes.*The NO TEARS tool for medication review*- Functions as a simple **aide-memoire** (Need, Objective, Toxicity, Efficacy, Adverse effects, Re-evaluation, Substitution) for general reviews.- It is less **evidence-based** and systematic than the STOPP/START criteria when dealing with complex, high-risk patients with multiple comorbidities.*The Anticholinergic Burden Scale*- Specifically evaluates the cumulative effect of **anticholinergic medications** on cognitive and physical function.- It is too narrow in scope and does not address the overall **appropriateness or omission** of drugs for heart failure, IHD, or diabetes.
Question 24: A 75-year-old woman with heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, and osteoarthritis takes 11 regular medications. She has been admitted to hospital twice in the past 6 months with acute decompensated heart failure. During a comprehensive medication review, you discover she has been taking ibuprofen 400mg three times daily (purchased over-the-counter) for knee pain for the past 8 months. What is the primary mechanism by which NSAIDs have contributed to her heart failure decompensation?
A. Direct myocardial toxicity leading to reduced contractility
B. Increased afterload due to peripheral vasoconstriction and sodium retention (Correct Answer)
C. Interference with the renin-angiotensin-aldosterone system blockade
D. Promotion of cardiac arrhythmias increasing ventricular filling pressure
E. Reduction in renal perfusion causing decreased diuretic effectiveness
Explanation: ***Increased afterload due to peripheral vasoconstriction and sodium retention***- **NSAIDs** inhibit **prostaglandins (PGE2 and PGI2)**, which are essential for maintaining **vasodilation** and promoting **sodium excretion (natriuresis)** in the kidneys.- The resulting **sodium and water retention** expands intravascular volume, while **peripheral vasoconstriction** increases **afterload**, both of which exacerbate heart failure symptoms and lead to decompensation.*Direct myocardial toxicity leading to reduced contractility*- **NSAIDs** do not possess a direct toxic effect on the cardiac **myocytes** or the contractile apparatus of the heart.- Heart failure exacerbation occurs through **hemodynamic changes** and fluid balance rather than structural or functional damage to cardiac tissue.*Interference with the renin-angiotensin-aldosterone system blockade*- While **NSAIDs** can attenuate the blood pressure-lowering effects of **ACE inhibitors**, this is a consequence of their renal actions rather than the primary cause of fluid overload.- This interference is a secondary interaction; the direct induction of **vasoconstriction** and **sodium retention** remains the dominant pathological mechanism.*Promotion of cardiac arrhythmias increasing ventricular filling pressure*- While chronic fluid overload and hypertension can eventually stretch the atria and trigger **atrial fibrillation**, **NSAIDs** are not primarily **arrhythmogenic** drugs.- The patient already has **atrial fibrillation**, but her decompensation is driven by **volume/pressure overload**, not a sudden change in heart rhythm induced by the ibuprofen.*Reduction in renal perfusion causing decreased diuretic effectiveness*- **NSAIDs** do decrease renal blood flow by inhibiting **prostaglandin-mediated afferent arteriolar vasodilation**, which can blunt the response to **loop diuretics**.- However, this is largely considered a component of the broader renal effects where **sodium retention** is the primary driver of the clinical presentation of edema and congestion.
Question 25: A 72-year-old man with chronic kidney disease stage 4 (eGFR 25 ml/min/1.73m²), type 2 diabetes, gout, and hypertension attends for review. His medications include insulin, allopurinol 100mg daily, amlodipine, doxazosin, and sodium bicarbonate. He reports three episodes of acute gout in the past 4 months despite treatment. His serum urate is 485 µmol/L (target <360 µmol/L). What is the most appropriate adjustment to his urate-lowering therapy?
A. Switch from allopurinol to febuxostat 80mg daily
B. Increase allopurinol to 200mg daily and monitor renal function closely (Correct Answer)
C. Add colchicine 500 micrograms twice daily as prophylaxis
D. Stop allopurinol and start probenecid 500mg twice daily
E. Continue current allopurinol dose and add benzbromarone
Explanation: ***Increase allopurinol to 200mg daily and monitor renal function closely***
- In patients with **chronic kidney disease (CKD)**, allopurinol should be started at a low dose and **gradually titrated upward** (by 50–100 mg increments) until the target serum urate level (<360 µmol/L) is reached.
- While the risk of **Allopurinol Hypersensitivity Syndrome** is higher in CKD, evidence supports that allopurinol can be safely used at doses >100 mg provided there is **careful monitoring** of renal function and clinical side effects.
*Switch from allopurinol to febuxostat 80mg daily*
- **Febuxostat** is typically reserved for patients who are intolerant of allopurinol or where allopurinol is contraindicated, rather than as a first-line escalation step.
- Current guidelines suggest caution with febuxostat in patients with severe **cardiovascular disease**, and it lacks the long-term safety profile of titrated allopurinol in this setting.
*Add colchicine 500 micrograms twice daily as prophylaxis*
- While **colchicine** is used for flare prophylaxis during the initiation of urate-lowering therapy, it does not address the underlying failure to reach the **target serum urate level**.
- In **CKD stage 4**, the dose of colchicine must be significantly reduced (e.g., 500 mcg every 2-3 days) to avoid toxicity, and twice daily dosing would be contraindicated.
*Stop allopurinol and start probenecid 500mg twice daily*
- **Probenecid** is a uricosuric agent that is largely **ineffective** in patients with an eGFR less than 30–50 ml/min/1.73m² because its mechanism depends on adequate renal filtration.
- Switching to an ineffective agent when a titration of the current effective medication is available would lead to poorly controlled **gout**.
*Continue current allopurinol dose and add benzbromarone*
- **Benzbromarone** is a potent uricosuric that can be used in renal impairment, but it is not commonly available and is typically reserved for specialist use only after allopurinol monotherapy fails.
- The priority remains to **optimize the dose** of allopurinol through titration before considering complex combination therapies or specialist-only medications.
Question 26: According to NICE Clinical Knowledge Summaries guidance on medication reviews in primary care, which statement best describes when a structured medication review should be prioritized?
A. All patients aged over 65 years should have an annual structured medication review regardless of the number of medications
B. Patients taking 4 or more regular medicines who have multimorbidity should be targeted for structured medication reviews (Correct Answer)
C. Structured medication reviews are only indicated for patients experiencing adverse drug reactions
D. Patients with a single long-term condition requiring 10 or more medications should be reviewed every 3 months
E. Medication reviews should be conducted every 6 months for all patients on anticoagulation therapy
Explanation: ***Patients taking 4 or more regular medicines who have multimorbidity should be targeted for structured medication reviews***- According to **NICE NG56 guidance**, patients with **multimorbidity** who are taking a significant number of regular medicines (typically **4 or more**) are a primary target group for structured medication reviews.- This prioritization aims to address the complexities of **polypharmacy**, minimize associated harms, and ensure treatment aligns with individual patient goals and clinical priorities.*All patients aged over 65 years should have an annual structured medication review regardless of the number of medications*- While patients over 65 are at increased risk of drug-related problems, NICE guidance does not advocate for a universal annual structured review based solely on **age**.- The focus is on individuals with **multimorbidity**, **polypharmacy**, and **frailty**, rather than age alone, to ensure targeted and efficient reviews.*Structured medication reviews are only indicated for patients experiencing adverse drug reactions*- Structured medication reviews are primarily a **proactive intervention** designed to prevent potential drug-related issues, optimize therapy, and improve patient outcomes.- Waiting for an **adverse drug reaction** to occur before conducting a review would be a reactive approach, contrary to the preventative aims of CKS guidance.*Patients with a single long-term condition requiring 10 or more medications should be reviewed every 3 months*- There is no specific NICE guidance mandating a **3-month review frequency** solely for patients on 10 or more medications for a *single* long-term condition.- The frequency of review is determined by clinical judgment, **risk assessment**, and the stability and complexity of the patient's overall health, with **multimorbidity** often being a more significant driver for frequent structured reviews.*Medication reviews should be conducted every 6 months for all patients on anticoagulation therapy*- While patients on **anticoagulation therapy** require careful and regular monitoring (e.g., INR or renal function), a full **structured medication review** is not universally mandated every 6 months for *all* such individuals.- Priority for structured reviews is typically given based on **multimorbidity** and overall clinical complexity, rather than solely on the presence of a single drug class.
Question 27: A 69-year-old woman attends for a medication review. She has type 2 diabetes, hypertension, atrial fibrillation, and hypothyroidism. She reports feeling 'generally well' but mentions occasional episodes of light-headedness when standing. Her current medications include metformin, gliclazide, amlodipine, ramipril, bisoprolol, apixaban, and levothyroxine. Her blood pressure today is 118/68 mmHg (sitting) and 95/60 mmHg (standing). What is the most appropriate next step in managing her medications?
A. Reduce the dose of amlodipine and review in 2 weeks (Correct Answer)
B. Stop bisoprolol immediately and switch to digoxin for rate control
C. Discontinue ramipril and monitor blood pressure closely
D. Add midodrine to treat the orthostatic hypotension
E. Replace gliclazide with a DPP-4 inhibitor to reduce hypoglycaemia risk
Explanation: ***Reduce the dose of amlodipine and review in 2 weeks***
- The patient exhibits symptomatic **orthostatic hypotension** with a significant **systolic blood pressure drop of 23 mmHg** upon standing, accompanied by light-headedness.
- **Amlodipine**, a dihydropyridine calcium channel blocker, is a potent vasodilator and contributor to orthostatic hypotension; its dose reduction is a safer initial step than altering medications vital for **organ protection** (ramipril) or **rate control** in atrial fibrillation (bisoprolol).
*Stop bisoprolol immediately and switch to digoxin for rate control*
- Abrupt discontinuation of **beta-blockers** like bisoprolol can lead to **rebound tachycardia**, myocardial ischemia, or worsening of angina.
- **Bisoprolol** is crucial for **rate control** in her **atrial fibrillation**, and switching to **digoxin** without a clear indication and with the risk of precipitating arrhythmias is inappropriate.
*Discontinue ramipril and monitor blood pressure closely*
- **Ramipril**, an ACE inhibitor, provides significant **renoprotection** in patients with **type 2 diabetes** and **hypertension**, which is a high-priority benefit.
- Discontinuing it without first attempting to reduce other BP-lowering agents would remove this crucial organ protection, which is generally maintained unless absolutely necessary.
*Add midodrine to treat the orthostatic hypotension*
- **Midodrine** is an alpha-1 adrenergic agonist used for orthostatic hypotension, but adding another drug to a patient already on **polypharmacy** is generally not the first step.
- The priority should be to identify and **deprescribe** medications contributing to the hypotension before introducing new drugs that increase complexity and potential side effects.
*Replace gliclazide with a DPP-4 inhibitor to reduce hypoglycaemia risk*
- The patient's symptoms are clearly related to **standing** and a measurable **blood pressure drop**, indicating **orthostatic hypotension**, not hypoglycemia.
- While **gliclazide** (a sulfonylurea) carries a risk of hypoglycemia, it is not the cause of the observed postural symptoms and replacing it would not address the primary issue.
Question 28: You are implementing a deprescribing initiative in your practice for patients with multimorbidity and polypharmacy. A 76-year-old man with heart failure (LVEF 42%), type 2 diabetes, hypertension, and previous stroke takes 14 regular medications including aspirin 75mg, clopidogrel 75mg, atorvastatin 80mg, ramipril 10mg, bisoprolol 10mg, furosemide 40mg, metformin 1g twice daily, sitagliptin 100mg, amlodipine 10mg, lansoprazole 30mg (started 4 years ago when dual antiplatelet therapy initiated), warfarin (INR target 2-3 for atrial fibrillation), levothyroxine 100mcg, and vitamin supplements. His stroke was 3.5 years ago. Which medication is most appropriate to consider for deprescribing?
A. Clopidogrel as 12 months of dual antiplatelet therapy post-stroke is sufficient
B. Lansoprazole as gastroprotection is no longer required with single antiplatelet therapy
C. Sitagliptin as dual therapy with metformin may be causing medication burden
D. Amlodipine as blood pressure may be adequately controlled without it
E. Aspirin as warfarin provides adequate anticoagulation (Correct Answer)
Explanation: ***Aspirin as warfarin provides adequate anticoagulation***
- In patients with **atrial fibrillation** requiring anticoagulation, adding **aspirin** to **warfarin** (or a DOAC) significantly increases the risk of **major bleeding** without providing additional benefit for stroke prevention.
- Given the stroke was 3.5 years ago, the need for dual antiplatelet therapy has passed, and combining an antiplatelet (aspirin) with an anticoagulant (warfarin) is generally contraindicated in favor of **anticoagulant monotherapy** for AF.
*Clopidogrel as 12 months of dual antiplatelet therapy post-stroke is sufficient*
- For **long-term secondary prevention** of non-cardioembolic stroke, a single antiplatelet agent like **clopidogrel** is often recommended and typically continued indefinitely, not limited to 12 months.
- Discontinuing clopidogrel while maintaining aspirin and warfarin would leave the patient on a less effective antiplatelet regimen for stroke prevention while still facing the high bleeding risk from the aspirin-warfarin combination.
*Lansoprazole as gastroprotection is no longer required with single antiplatelet therapy*
- This patient is on **warfarin** and **aspirin**, a combination that significantly elevates the risk of **gastrointestinal bleeding**, irrespective of previous dual antiplatelet use.
- Continuing a **proton pump inhibitor (PPI)** like lansoprazole is strongly recommended for **gastroprotection** in patients on anticoagulation, especially with concomitant antiplatelet therapy or other GI bleeding risk factors.
*Sitagliptin as dual therapy with metformin may be causing medication burden*
- **Sitagliptin** is a well-tolerated oral agent with a low risk of hypoglycemia, making it a suitable add-on to metformin for **Type 2 Diabetes** management to achieve glycemic targets.
- Deprescribing diabetes medication should be considered if the patient is experiencing hypoglycemia or if **HbA1c** is significantly below target, neither of which is indicated here, and it is a lower priority compared to high-risk bleeding combinations.
*Amlodipine as blood pressure may be adequately controlled without it*
- This patient has multiple strong indications for **strict blood pressure control**, including **heart failure**, **type 2 diabetes**, and a history of **stroke**.
- Removing **amlodipine** without evidence of hypotension or adequate control on fewer agents could lead to uncontrolled hypertension, increasing the risk of adverse cardiovascular and cerebrovascular events.
Question 29: A 66-year-old woman with rheumatoid arthritis, hypertension, type 2 diabetes, and recurrent urinary tract infections attends for medication review. Her medications include methotrexate 15mg weekly, folic acid 5mg weekly, sulfasalazine 1g twice daily, prednisolone 7.5mg once daily, omeprazole 20mg once daily, ramipril 5mg once daily, amlodipine 5mg once daily, metformin 1g twice daily, and she has been taking trimethoprim 200mg at night continuously for 9 months as prophylaxis prescribed by urology. Her most recent blood results show: eGFR 58 ml/min/1.73m², Hb 98 g/L (MCV 102 fL), WCC 3.2 × 10⁹/L. What is the most likely explanation for her blood results?
A. Methotrexate toxicity causing bone marrow suppression
B. Interaction between methotrexate and sulfasalazine causing megaloblastic anaemia
C. Trimethoprim-methotrexate interaction causing folate antagonism and marrow suppression (Correct Answer)
D. Chronic disease anaemia secondary to rheumatoid arthritis
E. Vitamin B12 deficiency secondary to long-term metformin use
Explanation: ***Trimethoprim-methotrexate interaction causing folate antagonism and marrow suppression***
- Both **methotrexate** and **trimethoprim** are potent **folate antagonists**; trimethoprim inhibits dihydrofolate reductase, leading to an additive effect that severely depletes folate levels.
- This pharmacological interaction causes **bone marrow suppression** and **pancytopenia**, explaining the patient's **macrocytic anaemia** (high MCV 102 fL) and **leucopenia** (low WCC 3.2
× 10⁹/L). The patient's eGFR of 58 ml/min/1.73m² would further increase methotrexate exposure, exacerbating this risk.
*Methotrexate toxicity causing bone marrow suppression*
- While **methotrexate** can cause **marrow suppression**, the patient is on a standard dose with **folic acid supplementation**, which significantly mitigates this risk in isolation.
- The continuous use of **trimethoprim** for 9 months, a strong folate antagonist, is the primary driver of the observed **pancytopenia** in this clinical context rather than methotrexate alone.
*Interaction between methotrexate and sulfasalazine causing megaloblastic anaemia*
- While **sulfasalazine** can have some folate antagonistic properties and occasionally interfere with folate absorption, it does not typically cause the severe additive **bone marrow suppression** seen with more potent antifolate antibiotics.
- The combination of **trimethoprim** and **methotrexate** is clinically much more potent and a higher risk for rapid and significant **hematologic decline** than with sulfasalazine.
*Chronic disease anaemia secondary to rheumatoid arthritis*
- **Anaemia of chronic disease** typically presents as **normocytic** or mildly microcytic, whereas this patient clearly has **macrocytosis** (MCV 102 fL).
- Furthermore, it would not explain the accompanying **leucopenia**, as chronic inflammation generally results in normal or sometimes elevated white blood cell counts, not a decrease.
*Vitamin B12 deficiency secondary to long-term metformin use*
- Long-term **metformin** use can cause **vitamin B12 deficiency**, which can lead to **macrocytic anaemia**.
- However, B12 deficiency is rarely the sole cause of significant **leucopenia** in this context, and the combined use of two strong folate antagonists provides a much more direct and comprehensive explanation for both the macrocytic anaemia and leucopenia.
Question 30: During a practice audit of medication reviews, you identify that 25% of patients over 75 years taking 10 or more medications have not had a structured medication review in the past 12 months. You are planning a quality improvement intervention. According to best practice guidance, which component is most essential to include in a structured medication review process for this population?
A. Checking concordance by counting remaining tablets in dispensed bottles
B. Assessing the indication, effectiveness, safety, and patient experience for each medication (Correct Answer)
C. Ensuring all medications are prescribed as branded products to avoid confusion
D. Conducting annual blood tests including full blood count, renal, and liver function
E. Referring all complex patients to clinical pharmacology for specialist review
Explanation: ***Assessing the indication, effectiveness, safety, and patient experience for each medication***- A **structured medication review (SMR)** must be a comprehensive, person-centered assessment that ensures every drug has a valid **indication** and yields the desired **clinical benefit**.- This approach aligns with the **7-step medication review process**, prioritizing **patient preferences** and safety to reduce the risks associated with **polypharmacy** and adverse drug reactions.*Checking concordance by counting remaining tablets in dispensed bottles*- While **pill counts** can identify potential non-compliance, they are an unreliable and outdated method for assessing **long-term adherence** and do not address the clinical logic of the prescription.- This focus is too narrow and fails to evaluate if the medications remain **effective** or necessary for the patient's current health status.*Ensuring all medications are prescribed as branded products to avoid confusion*- **Generic prescribing** is standard practice in primary care to ensure **cost-effectiveness**; switching to branded products without clinical justification is generally discouraged.- Confusion is better managed through the use of **patient information leaflets**, compliance aids, or simplifying the **medication regimen** rather than branding.*Conducting annual blood tests including full blood count, renal, and liver function*- While **monitoring** organ function is a vital safety component for specific drugs, these tests are not a universal requirement for every single medication in a review.- Blood tests are a **subset of the safety assessment** but do not constitute a full review of clinical need or patient experience.*Referring all complex patients to clinical pharmacology for specialist review*- Most medication reviews should be managed within **primary care** by general practitioners or **clinical pharmacists** who are familiar with the patient's holistic history.- Specialist referral is reserved for **complex diagnostic dilemmas** or highly specialized therapies, and routine referral is not an efficient or recommended use of resources.
